Sarepta Therapeutics Inc to Announce Results of Phase I/IIa Gene Transfer Clinical Trial using MYO-101 - Conference Call Transcript
Good morning, ladies and gentlemen, and welcome to the Sarepta Therapeutics limb-girdle muscular dystrophy type 2E data conference call. As a reminder, today's program is being recorded. I'll now turn the call over to Doug Ingram, President and CEO of Sarepta Therapeutics. Please go ahead.
Thank you very much. This is Doug Ingram. I'm the Chief Executive Officer for Sarepta. Thank you for joining our webcast this morning to report the results of our first cohort of patients in our limb-girdle 2E program. Please understand that we will be making forward-looking statements, and I would refer you to our public filings for obviously the various risks and uncertainties that come with making forecasts about the future.
We're excited to be reporting results today. This is an extremely important milestone for Sarepta. Our collaborator, Dr. Jerry Mendell wishes he could be with us today, and he sends his well wishes, but he is in Columbus, Ohio, and he's continuing to dose patients in
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |